ProShare Advisors
XERS icon

ProShare Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

ProShare Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223K Sell
28,115
-2,365
-8% -$15.1K ﹤0.01% 1584
2026
Q1 		$177K Sell
30,480
-4,910
-14% -$32.6K ﹤0.01% 1620
2025
Q4 		$278K Buy
35,390
+3,383
+11% +$26.6K ﹤0.01% 1504
2025
Q3 		$261K Sell
32,007
-4,716
-13% -$31.3K ﹤0.01% 1527
2025
Q2 		$171K Sell
36,723
-358
-1% -$1.64K ﹤0.01% 1761
2025
Q1 		$204K Sell
37,081
-9,472
-20% -$38.2K ﹤0.01% 1674
2024
Q4 		$158K Sell
46,553
-24,051
-34% -$77.4K ﹤0.01% 1956
2024
Q3 		$201K Buy
70,604
+43,630
+162% +$112K ﹤0.01% 1728
2024
Q2 		$60.7K Sell
26,974
-6,614
-20% -$13.3K ﹤0.01% 1722
2024
Q1 		$74.2K Buy
33,588
+2,739
+9% +$7.09K ﹤0.01% 1862
2023
Q4 		$72.5K Buy
30,849
+4,537
+17% +$8.37K ﹤0.01% 1818
2023
Q3 		$48.9K Buy
26,312
+122
+0.5% +$279 ﹤0.01% 1717
2023
Q2 		$68.6K Buy
26,190
+1,179
+5% +$3K ﹤0.01% 1742
2023
Q1 		$40.8K Buy
+25,011
New +$31.3K ﹤0.01% 1686
2022
Q4 		– Sell
-26,029
Closed -$41K – 1894
2022
Q3 		$41K Buy
26,029
+601
+2% +$994 ﹤0.01% 1678
2022
Q2 		$39K Buy
25,428
+11,445
+82% +$24.2K ﹤0.01% 1731
2022
Q1 		$36K Sell
13,983
-3,578
-20% -$8.74K ﹤0.01% 2140
2021
Q4 		$51K Buy
17,561
+3,356
+24% +$7.25K ﹤0.01% 2283
2021
Q3 		$35K Buy
14,205
+2,280
+19% +$6.62K ﹤0.01% 1986
2021
Q2 		$49K Sell
11,925
-8,539
-42% -$32.6K ﹤0.01% 2359
2021
Q1 		$92K Buy
20,464
+2,723
+15% +$14.7K ﹤0.01% 2176
2020
Q4 		$87K Buy
17,741
+4,651
+36% +$23.3K ﹤0.01% 2006
2020
Q3 		$78K Buy
13,090
+2,010
+18% +$8.04K ﹤0.01% 1551
2020
Q2 		$29K Buy
+11,080
New +$38.6K ﹤0.01% 1647
2019
Q4 		– Sell
-10,344
Closed -$102K – 1804
2019
Q3 		$102K Buy
10,344
+314
+3% +$3.53K ﹤0.01% 1546
2019
Q2 		$115K Sell
10,030
-1,291
-11% -$13.6K ﹤0.01% 1517
2019
Q1 		$114K Buy
+11,321
New +$145K ﹤0.01% 1559

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ProShare Advisors's XERS Position: Q2 2026 in Review

ProShare Advisors reduced its Xeris Biopharma Holdings (XERS) stake by 7.8% in Q2 2026, selling an estimated $15.1K and leaving 28,115 shares worth $223K. The position accounts for ﹤0.01% of the portfolio, ranked #1584.

ProShare Advisors first reported a position in XERS in Q1 2019 and has held it in 27 quarters since. The position peaked at $278K in Q4 2025. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • ProShare Advisors held 28,115 shares of Xeris Biopharma Holdings worth $223K as of Q2 2026.
  • ProShare Advisors sold 2,365 Xeris Biopharma Holdings shares in Q2 2026, an estimated $15.1K.
  • Xeris Biopharma Holdings made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1584 holding.
  • ProShare Advisors first reported a position in Xeris Biopharma Holdings in Q1 2019 and has held it in 27 quarters since.
  • ProShare Advisors's Xeris Biopharma Holdings position peaked at $278K in Q4 2025.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.